Table 2.
Comparison of quetiapine doses in different subgroups of patients (XR and IR group not shown)
| XR group |
IR group |
p Value | |||||
| Mean | 95% CI | N | Mean | 95% CI | N | ||
| Mean doses during inpatient stay | |||||||
| All patients | 583.7 | 499.7 to 667.6 | 43 | 341.0 | 267.9 to 414.1 | 58 | <0.001 |
| Women | 579.1 | 472.4 to 685.8 | 18 | 295.1 | 185.7 to 404.5 | 28 | <0.001 |
| Men | 587.0 | 458.1 to 715.9 | 25 | 383.9 | 282.3 to 485.5 | 30 | 0.013 |
| SCZ | 622.0 | 508.4 to 735.6 | 28 | 328.1 | 244.4 to 411.8 | 44 | <0.001 |
| BD | 512.1 | 389.4 to 634.8 | 15 | 381.6 | 212.2 to 551.0 | 14 | 0.186 |
| Patients aged >45 years* | 535.3 | 427.1 to 643.5 | 13 | 295.6 | 207.8 to 383.3 | 30 | 0.002 |
| Patients aged ≤45 years* | 604.6 | 490.8 to 718.5 | 30 | 389.7 | 267.6 to 511.8 | 28 | 0.011 |
| Maximum dose during inpatient stay | 672.1 | 580.9 to 763.3 | 43 | 459.1 | 352.8 to 565.3 | 58 | 0.004 |
| Mean dose at discharge† | 630.3 | 527.5 to 733.1 | 33 | 394.1 | 290.1 to 498.2 | 34 | 0.002 |
Mean age in the study population.
Among patients who were discharged with the study drug.
BD, bipolar disorder; SCZ, schizophrenia spectrum disorder.